John McCamant

John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000. Mr. McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.

Read More

The Medicines Company (MDCO)

This drug maker hammered analysts’ earnings estimates, posting EPS of $2.62 last quarter, vs. the -$1.16 previously forecast. Analysts are forecasting double-digit growth rates for the rest of this year. The Medicines Company (MDCO)From The Medical Technology Stock Letter On its Q2 quarterly call, The Company...
Read More

Novavax, Inc. (NVAX)

This biotech missed analysts’ forecasts last quarter, losing $0.29 per share, compared to the estimated loss of $0.15. However, clinical trials are promising, and a takeover/partnership could soon be in the works. Two analysts have raised their 2017 earnings estimates in the past days. Novavax,...
Read More

Medical Technology Stock Letter

The Medical Technology Stock Letter (MTSL) provides solid investment advice based on company and industry fundamentals. Our thirty years of experience in providing investment advice for this unique and volatile sector gives MTSL and YOU the edge. Our insistence on thorough research and of...
Read More

Acadia Pharmaceuticals (ACAD)

New data for this drug company’s Parkinson’s disease treatment, its agreement with BASF Pharma who will manufacture and supply the active ingredient of NUPLAZID, and its undervalued price prompted Piper Jaffrey to upgrade the shares to “Overweight.” Acadia Pharmaceuticals (ACAD) from Medical Technology Letter Acadia (ACAD)...
Read More

Pharmacyclics (PCYC)

As I mentioned in my blog post last week, here is an update on the PCYC/ABBV merger. Bottom line recommendation: hold onto your ABBV stock, post-merger. Hold Pharmacyclics (PCYC) from The Medical Technology Stock Letter Updated from Investment Digest 759, July 23, 2014 Mid-Year Top Picks may...
Read More

Pharmacyclics (PCYC)

Today’s 2014 Top Picks update is a biotech whose earnings estimates are trending up. This contributor has also increased his price target for the shares. Pharmacyclics (PCYC) from The Medical Technology Stock Letter In January, Pharmacyclics (PCYC) released highly positive data from the RESONATE trial, the Phase...
Read More

Novavax (NVAX)

This biotech company just completed a successful Phase 2 clinical trial for its respiratory illness vaccine for women of childbearing age. Please note that shares of biotech companies are speculative in nature and should be allocated to a small percentage of your overall (NVAX) from...
Read More

OncoGenex Pharmaceuticals (OGXI)

This biopharmaceutical company has two drug candidates in clinical development across multiple oncology therapeutic areas and a candidate in pre-clinical development. OncoGenex’Pharmaceuticals (OGXI) from The Medical Technology Stock Letter OncoGenex Pharmaceuticals’ (OGXI ) custirsen could dominate second-line hormone resistant prostate cancer (HRPC) therapy. Medivation’s Xtandi has positive...
Read More

Novavax (NVAX)

Today we have a thoroughly researched new recommendation of a small-cap biotech stock from The Medical Technology Stock Letter. “While we are proud of the MTSL Portfolio performance YTD, most our Recommended Stocks currently trade above their respective buy limits. Unlike most Wall Street we...
Read More